From SNPedia
| ? | (C;C) (C;T) (T;T) | 28 |
|---|
 |
SNP, defining the CYP2C8*3 allele (along with
rs11572080).
Individuals carrying this SNP may show increased risk of developing acute gastrointestinal bleeding during the use of NSAIDs that are CYP2C8 or CYP2C9 substrates, such as aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.[PMID 19422321]
| PharmGKB | PA162361002 |
| Name | CYP2C8: K399R, A1196G, CYP2C8*3 |
| Annotation | Risk or phenotype-associated allele: G. Phenotype: In woman, the risk of acute myocardial infarction (AMI) tended to be higher for subjects carrying the CYP2C8*3*3 genotype versus *1*1 (OR = 1.9). The CYP2C8*3 variants are 416G>A (rs10509681) and 1196A>G (rs11572080). Tested in all subjects, the risk of AMI was also higher in individuals carrying the CYP2C8*3 allele (*3*3; *1*3 versus*1*1) [1.2 (1.0-1.5), P = 0.07]. Study size: 1172 AMI patients and 1503 control subjects. Study population: Caucasian. |
| Gene | CYP2C8 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:14646690 |
| Drugs | |
| Diseases | Myocardial Infarction |
| Curation Level | Curated |
| PharmGKB | PA161660769 |
| Name | CYP2C8: K399R, A1196G |
| Annotation | The variant is part of the CYP2C8*3 allele. In in vitro studies, the recombinant expressed CYP2C8*3 exhibits markedly impaired metabolism of paclitaxel and arachidonic acid. |
| Gene | CYP2C8 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:11668219 |
| Drugs | paclitaxel |
| Diseases | |
| Curation Level | Curated |
| PharmGKB | PA161660865 |
| Name | CYP2C8: K399R, A1196G, CYP2C8*3 |
| Annotation | Different literature sources show a discrepancy between several in vitro findings describing a lower activity of the CYP2C8*3 variant and in vivo findings showing higher oral clearance in *3 allele carriers at least for some substrates of CYP2C8. A study on healthy volunteers administered with repaglinide found that the CYP2C8*3 variant allele was associated with reduced plasma concentrations of repaglinide. Another study showed that subjects carrying the CYP2C8*3 allele had a lower rosiglitazone plasma concentration. |
| Gene | CYP2C8 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:14534525; PubMed ID:17178266 |
| Drugs | repaglinide, rosiglitazone |
| Diseases | |
| Curation Level | Curated |
| PharmGKB | PA162360173 |
| Name | CYP2C8: K399R, A1196G, CYP2C8*3 |
| Annotation | CYP2C8*3 has no detectable amodiaquine metabolism activity in vitro. |
| Gene | CYP2C8 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:18855526 |
| Drugs | amodiaquine |
| Diseases | Malaria |
| Curation Level | Curated |
| PharmGKB | PA162361000 |
| Name | CYP2C8: K399R, A1196G, CYP2C8*3 |
| Annotation | CYP2C8*3 allele (containing Arg139Lys and Lys399Arg) is associated with increased the clearance of meglitinides. |
| Gene | CYP2C8 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:17963417 |
| Drugs | |
| Diseases | Diabetes Mellitus, Type 2 |
| Curation Level | Curated |
